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 Abstract 
  Background/Aims:   Alzheimer disease (AD) is a complex and genetically heterogeneous disor-
der, and certain genes such as PS2 and APOE4 contribute to the development of AD. Due to its 
heterogeneity, AD-predisposing genes could vary in different populations. Moreover, not all AD 
patients will respond to the same therapy. We specifically investigated the effect of   rivastigmine 
(Exelon) on PS2 and APOE genes in Iranian AD patients.  Methods:  A total of 100 AD patients, 67 
patients with sporadic AD (SAD) and 33 patients with familial AD (FAD), receiving rivastigmine 
therapy and 100 healthy controls were studied.     PCR-RFLP was used for genotyping of PS2 and 
APOE.   Results:   We found a positive association between the PS2 –A allele and SAD patients
(p  c   = 0.01), and the PS2 +A/–A genotype was significantly more frequent in SAD than FAD pa-
tients (p  c  = 0.009). The APOE4 allele was associated with total AD, SAD and FAD (p  c  = 0.000002). 
Patients with the PS2 +A/–A genotype and bigenic genotypes of +A/–A    3/  3 and +A/–A    3/  4 
were the best responders to Exelon therapy, and those with the PS2 +A/+A and APOE    3/  4 
genotypes were the worst responders.   Conclusion:   Our findings suggest that the PS2 and 
APOE4 alleles and genotypes affect both AD risk and response to rivastigmine therapy. 
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 Introduction 
  Alzheimer disease (AD) is the most common progressive neurodegenerative disorder 
leading to dementia in the elderly, with increasing prevalence in the near future. The inci-
dence of the disease rises with age, and about 10% of individuals   1  70 years have significant 
memory loss and in   1  50% of them AD occurs. It is estimated that about 25–45% of individ-
uals  1 85 years old have dementia. The prevalence of AD increases from 2.8 per 1,000 person 
years in the 65- to 69-year age group to 56.1 per 1,000 person years in those   1 90  years   [1] . 
AD is the 4th cause of death in modern societies, with progressive impairment in memory 
and intellectual function resulting in death   [2, 3]  .
    AD is a multifactorial and heterogeneous disease   [4]  . Both genetic and environmental 
factors are supposed to be involved in disease predisposition. A number of case-control stud-
ies have demonstrated associations of some polymorphic genes, such as apolipoprotein E4 
(ApoE4), angiotensin-converting enzyme, presenilin 1 (PS1), presenilin 2 (PS2) and amyloid 
precursor protein (mostly single-nucleotide polymorphisms), with AD   [2, 5–10]  . In 1993, 
Corder et al.   [7]   reported that 40–50% of the risk for late-onset AD is attributable to ApoE 
alleles. An association of a polymorphism in the regulatory region of the PS2 gene with AD 
was also found  [9, 10] . Mutations in the presenilin gene increase the production of an altered 
form of     -amyloid, called A42, as suggested by Scheuner et al.   [11]   in 1996. Mutations in 
PS2 cause a less severe AD phenotype, which is due to its lower expression in the brain com-
pared to the PS1 gene   [12]  . Therefore, polymorphisms affecting the promoter region of PS2 
could either increase or decrease the risk for AD.     However, the complex nature of AD with 
its multifactorial inheritance and more importantly its heterogeneity could lead to the hy-
pothesis that associations with some of these predisposing genes could vary in different AD 
populations   [7–10, 13]  .
    Since the production of the first cholinesterase inhibitor in 1997, most clinicians con-
sider cholinergic drugs such as rivastigmine (Exelon) in the first-line treatment for mild-to-
moderate AD. By blocking the acetyl cholinesterase enzyme, the drug inhibits the break-
down of acetylcholine, an important neurotransmitter associated with memory, resulting in 
slight improvement in cognition and memory. Recent studies have shown that the above-
mentioned predisposing genes could mediate the response of patients to drugs  [14–16] . More-
over, pioneering pharmacogenetic studies have demonstrated that the therapeutic response 
in AD may be genotype specific under different pharmacogenomic conditions   [17, 18]  .
    Considering the importance of the geographical location, ethnical background of the 
patients and also the heterogeneity of the disease, in the present study we investigated the 
influence of Exelon on two Iranian AD patient groups: patients carrying APOE and PS2 sus-
ceptibility genes and those not carrying these genes.
  Patients  and  Methods 
  Patients and Controls 
  In the present study, a total of 100 patients (mean age: 77.7   8   7.6 years, range: 61–96; 50 
males: mean age: 77.7   8   1 years, range: 62–87, and 50 females: mean age: 78.4   8   7.5 years, 
range: 61–96) with AD diagnosed based on the NINCDS-ADRDA/DSM-IV clinical diagnos-
tic criteria   [19]  , CT and MRI have been studied in the Department of Neurogenetics of the 
Iranian Center of Neurological Research. Of 100 AD patients, 67 cases (mean age: 77.6  8  7.1 
years, range: 61–92) had sporadic AD (SAD) and 33 cases (mean age: 77.8  8  8.5 years, range: 
62–96) familial AD (FAD). All SAD and FAD patients were unrelated and received a stan-
dard dose of rivastigmine (Exelon) for 1 year. A neurologist clinically assessed the patients, 182
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and clinical information, such as gender, age, age at disease onset and family history, was 
recorded in questionnaire form. To evaluate the severity of AD, mild cognitive impairment 
and response to rivastigmine, Clinical Dementia Rating scale Sum of Boxes (CDR-SB) scores 
were assessed accurately at baseline and after 3, 6, 9 and 12 months of treatment.
    One hundred healthy volunteers without any signs of dementia who were matched for 
age/sex and ethnic background were chosen after assessing their cognitive function using 
the Mini-Mental State Examination   [10]  . They were selected from the same geographic re-
gions as the patients. All the patients or their legal guardians and control subjects gave their 
informed consent before being included in the study, which was approved by a local ethics 
committee.
    PS2 and APOE Genotyping 
 Blood samples were drawn from each individual, and genomic DNA was extracted from 
peripheral blood samples using a modified salting-out method   [20]  . Polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP) was used for PS2 and APOE 
genotyping. PS2 polymorphisms were detected by PCR using forward (5   -TAAACTGTGG-
CATACATGA-3    ) and reverse primers (5   -CCATACCCATTGAGAAGGT-3   ) as described 
previously   [21]  . PCR was performed according to the following protocol: 5 min at 94    °   C  fol-
lowed by 33 cycles for 30 s at 94    °    C, 30 s at 57    °    C, 60 s at 72    °    C, and 5 min at 72    °    C as final ex-
tension. The PCR products were digested with  Dde  I restriction endonuclease under optimal 
condition and were electrophoresed in 8% polyacrylamide gel. After staining with ethidium 
bromide, the bands were visualized using a gel documentation system. APOE genotyping 
was performed using previously described forward (5   -TAAGCTTGGC ACGGCTG TCC-
AA GGA-3  ) and reverse (5-ACAGAATTCGCCCCGGCCTGGTACAC-3  ) primers  [22]  and 
the following PCR method: preliminary DNA denaturation at 94    °    C for 5 min, followed by 
33 cycles of DNA denaturation at 94    °    C for 30 s, annealing at 64    °    C for 30 s and polymeriza-
tion at 72    °   C for 60 s. The final extension step was at 72    °   C for 10 min. The PCR products were 
digested with   Hha  I restriction endonuclease under optimal condition. Then the digested 
products were electrophoresed on 7% polyacrylamide gel and were visualized with ethidium 
bromide.
  Statistical  Analysis 
  All data were entered into a database and analyzed with SPSS, version 16, for Windows. 
Differences in the frequencies of APOE and PS2 alleles and the genotypes between the pa-
tient and control groups were determined using Fisher’s exact test or the    2  test when appro-
priate. Two-tailed Student’s t test was used to compare quantitative data. After Bonferroni’s 
correction for multiple comparisons, corrected p (p  c )   !   0.05 was assumed to be statistically 
significant.
  R e s u l t s  
 Genetic  Analysis 
  The distribution of PS2 and APOE allele and genotype frequencies in AD patients and 
healthy controls are shown in   table 1  . The genotypes of these genes were in Hardy-Weinberg 
equilibrium for both groups. As shown in   table 1  , there was no significant association be-
tween PS2 alleles and genotypes between the AD and control groups. When AD patients 
were stratified according to family history (FAD and SAD), a significant positive association 
between the PS2 –A allele and SAD patients was found (p  c  = 0.01). Comparison of the APOE 
allele distribution in the AD and control groups demonstrated a significant difference be-183
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tween the two groups. The APOE4 allele was positively associated and the APOE3 allele was 
negatively associated with total AD, SAD and FAD (  table 1  ). The results also indicated that 
in contrast to the APOE    3/   3 genotype, which was significantly more frequent in controls, 
the APO    3/   4 genotypes were significantly more frequent in total AD, SAD and FAD pa-
tients than in controls, and these differences were statistically significant (  table 1  ).
    Comparisons of PS2 and APOE allele and genotype frequencies in SAD and FAD pa-
tients are shown in   table 2  . Sixty-seven percent of the patients had SAD and 33% had FAD. 
The results also showed that the +A/–A genotype of PS2 was significantly more frequent in 
SAD than FAD (p  c   = 0.009). There were no statistically significant differences in PS2 and 
APOE allele or genotype frequencies between SAD and FAD patients.
  Response  to  Rivastigmine 
  Monogenic-Related Drug Response . PS2- and APOE-associated responses to Exelon ther-
apy in AD patients are shown in   figures 1   and   2  . Analysis of drug response according to 
various genotypes showed that AD patients with the PS2 +A/–A genotype were the best re-
sponders among all AD patients. In this group of AD patients, disease progression is not 
significantly different compared to baseline. In contrast, patients with the PS2 +A/+A and 
APO   3/   4 genotypes were the worst responders, with severity of disease being significantly 
increased after treatment with Exelon compared to baseline. Other genotype frequencies 
were low and their therapeutic response was not identified.
   Drug Response according to Gender and Monogenic Genotype.   PS2- and APOE-associat-
ed responses to Exelon therapy in male and female AD patients are shown in   figures 3   and   
4  , respectively. When drug response is analyzed in relation to gender and different mono-
genic genotypes of these two genes, both male and female AD patients with the PS2 +A/–A 
genotype were the best responders. In other genotype carriers, slight progression of disease 
was noted compared to baseline.
Table 1.   The distribution of PS2 and APOE allele and genotype frequencies in 100 Iranian AD patients and 100 healthy
controls
All AD
patients
(n = 100)
Controls
(n = 100)
SAD
patients
(n = 67)
FAD
patients
(n = 33)
All AD vs. controls SAD vs. controls F  AD vs. controls
pc  OR (95% CI) pc OR (95% CI) pc  OR (95% CI)
Alleles
PS2
+A 165 179 106 59 0.06 0.55 (0.32–0.99) 0.01 0.44 (0.24–0.82) NS
–A 35 21 28 7 0.06 1.81 (1.01–3.13) 0.01 2.25 (1.022–4.09) NS
APOE
E2 6 13 4 2 NS NS NS
E3 152 177 102 50 0.001 0.42 (0.24–0.71) 0.003 0.41 (0.23–0.75) 0.01 0.41 (0.20–0.81)
E4 42 10 28 14 2!10–6 4.86 (2.43–9.75) 0.00001 5.02 (2.33–10.11) 0.0002 5.12 (2.17–11.55)
Genotypes
PS2
+A/+A 69 79 41 28 NS 0.01 0.42 (0.22–0.83) NS
+A/–A 27 21 24 3 NS 0.049 2.10 (1.05–4.11) NS
–A/–A 4 0 2 2 NS NS NS
APOE
33 58 77 39 19 0.006 0.42 (0.23–0.76) 0.01 0.042 (0.22–0.81) 0.04 0.41 (0.18–0.92)
34 33 10 22 11 0.001 4.28 (2.02–9.05) 0.0004 4.40 (1.91–9.50) 0.004 4.50 (1.73–11.25)
44 3 0 2 1 NS NS NS
24 3 0 2 1 NS NS NS
23 3 13 2 1 0.02 0.23 (0.07–0.73) 0.02 0.21 (0.07–0.90) NS
Fis  her’s exact test with correction (2 tailed). All significant pc are shown in bold.184
Dement Geriatr Cogn Disord Extra 2011;1:180–189
 DOI:  10.1159/000329514 
EXTRA
  Zamani et al.: Pharmacogenetic Study on Rivastigmine in Iranian AD Patients 
www.karger.com/dee
    © 2011 S. Karger AG, Basel
  Published online: June 29, 2011 
   Bigenic Genotype-Related Drug Response.   Bigenic genotype-related responses to Exelon 
therapy in AD patients are shown in   figure 5  . Our findings indicated that bigenic genotypes 
+A/–A    3/   3 and +A/–A     3/   4 carriers were the best responders to Exelon therapy.
  Discussion 
  AD is a complex and genetically heterogeneous disorder. Twin and family studies have 
indicated that certain genes contribute to the development of AD. Among those, mutations 
in PS2 on chromosome 1 and APOE on chromosome 19 have been shown to play an impor-
tant role in the pathogenicity of AD   [9, 11, 23]  . Based on the complex nature of AD with its 
numerous possible associated gene mutations and more importantly the heterogeneity of the 
disease, it is highly probable that some of these AD-predisposing genes could vary among 
different AD populations  [7–10, 13] . Moreover, it seems that not all AD patients will respond 
to a given therapy due to disease heterogeneity at molecular level. This assumption is sup-
ported by the study by Schneider and Farlow   [24]   in 1995, which indicated that only up to 
50% of AD patients had a significant response to acetylcholine esterase inhibitors.
    In this study, we investigated both the contribution of APOE and PS2 alleles and geno-
types regarding the risk of AD and, for the first time, the influence of     Exelon (an acetylcho-
line esterase inhibitor) on two Iranian AD patient groups: patients with or without the sus-
ceptibility genes APOE and PS2.
    We found no significant association between PS2 alleles or genotypes and total AD pa-
tients compared to controls. However, after stratifying AD patients according to family his-
tory (FAD and SAD), a significant positive association was found between the PS2 –A allele 
and SAD patients (p  c   = 0.01). In 2002, for the first time, Riazanskaia et al.   [21]   detected a 
Table 2.   The distribution of PS2 and APOE allele and genotype frequencies in
Iranian SAD and FAD patients
SAD patients
(n = 67)
FAD patients
(n = 33)
SAD vs. FAD
pc OR (95% CI)
Alleles
PS2
+A 106 59 0.078 0.45 (0.20–1.10)
–A 28 7 0.078 2.23 (0.91–4.94)
APOE
E2 4 2 NS
E3 102 50 NS
E4 28 14 NS
Genotypes
PS2
+A/+A 41 28 0.030 0.28 (0.11–0.82)
+A/–A 24 3 0.009 5.58 (1.55–15.52)
–A/–A 2 2 NS
APOE
33 39 19 NS
34 22 11 NS
44 21N S
24 21N S
23 21N S185
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polymorphism in the 5  -upstream promoter region of the PS2 gene caused by a single adenos-
ine nucleotide deletion located between   –  1,500 and   –  1,600 bp upstream from the transcrip-
tion start site. The wild type of the polymorphic sequence (PS2 +A) is similar to the inter-
feron regulatory factor (IRF-2). It acts as repressor of transcription. The deletion polymor-
phism (PS2 –A) created a new potential regulatory site for the transcription factor C/EBF 
  Fig. 1.  PS2 genotype-related ther-
apeutic response to Exelon ther-
apy in 100 Iranian AD patients.
a coef. = y-intercept of the line;
b coef. = slope or gradient of the 
line.  
  Fig. 2.   APOE  genotype-related 
therapeutic response to Exelon 
therapy in 100 Iranian AD pa-
tients. a coef. = y-intercept of the 
line; b coef. = slope or gradient of 
the line.  
  Fig. 3.   PS2 and APOE genotype-
related therapeutic response to 
Exelon therapy in male AD pa-
tients. a coef. = y-intercept of the 
line; b coef. = slope or gradient of 
the line.  186
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(CCAAT/enhancer) which leads to the promotion of transcription and finally the rise in pep-
tide fragments of amyloid precursor proteins   [21]  . In agreement with the studies of Riazan-
skaia et al.   [21]   in 2002 and Liu and Jia   [10]   in 2008, our findings showed an association of 
the   –  A allele with the risk of AD but were in contrast to studies performed in Italian, Japa-
nese and Polish populations  [9, 13, 25] . This could be due to the genetic heterogeneity of AD, 
ethnic and regional differences and also sample size. Our results also showed that the PS2 
+A/–A genotype is significantly more frequent in SAD than FAD (p  c   = 0.009). Collectively, 
these findings suggested that the   –  A allele and the +A/–A genotype of PS2 may affect the 
SAD risk in Iranians.
    In agreement with several studies performed in different ethnic groups   [26–28]  , our 
findings demonstrated that the APOE4 allele and    3/   4 genotypes were positively and the 
APOE3 allele negatively associated with total AD, SAD and FAD (  table 1  ). Our results were 
not in agreement with a few studies performed on Nigerian and East-African populations, 
in which the results did not show any correlations   [29, 30]  . Nevertheless, our findings indi-
cated that the APOE4 allele is a genetic risk factor for both SAD and FAD in the Iranian 
population. However, the underlying mechanism(s) showing how APOE4 affects AD risk 
and progression remain to be elucidated. However, evidence accumulates that the differen-
tial effects of     APOE4 on amyloid      aggregation and clearance play the main role in AD 
pathogenesis. Other potential mechanisms, such as cholesterol/phospholipid homeostasis 
  Fig. 4.   PS2 and APOE genotype-
related therapeutic response to 
Exelon therapy in female AD pa-
tients. a coef. = y-intercept of the 
line; b coef. = slope or gradient of 
the line.  
  Fig. 5.   Combined APOE and PS2 
genotype-related therapeutic re-
sponse to Exelon therapy in AD 
patients. a coef. = y-intercept of 
the line; b coef. = slope or gradi-
ent of the line.  187
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and synaptic integrity, the modulation of neurotoxicity and tau phosphorylation, as well as 
its role in neuronal survival may also be effective in AD pathogenesis   [15]  .
  Numerous pharmacogenetic studies have demonstrated that the therapeutic response in 
AD seems to be genotype specific under different pharmacogenomic conditions and it is also 
influenced by gender   [17, 18]  . We investigated these hypotheses in Iranian AD patients, and 
our results indicated that patients with the PS2 +A/–A genotype were the best responders 
and patients with the PS2 +A/+A and APOE   3/  4 genotypes were the worst responders. The 
exact mechanisms through which the PS2 genotype status affects response to certain acetyl-
choline esterase inhibitors are still unknown but in terms of the APOE genotype, this may 
not be surprising because the APOE4 gene has been found to influence choline acetyltrans-
ferase activity in the cortex and hippocampus   [31, 32]  , and the number of copies of APOE 
alleles was inversely related with residual choline acetyltransferase activity in the brain   [15]  . 
Our results revealed that both male and female AD patients with PS2 +A/–A were the best 
responders. In contrast with the results of Farlow et al.   [33]   in 1996, our study did not reveal 
any significant effect of ApoE on response to therapy in males or females. Regarding the bi-
genic genotype-related therapeutic response to Exelon therapy, the results indicated that 
+A/–A    3/   3 and +A/–A     3/   4 genotype carriers were the best responders. These findings 
might demonstrate that gene-gene interactions and also different polymorphic variants in-
volved in AD pathogenesis may affect the therapeutic response of AD patients.
    In conclusion, our findings suggested that the PS2   U  A allele and the +A/–A genotype 
contribute to the SAD risk. The results also demonstrated that the APOE4 allele is a genetic 
risk factor for both SAD and FAD in Iranian AD patients. Moreover, patients with the PS2 
+A/–A genotype and bigenic genotype carriers of +A/–A     3/   3 and +A/–A     3/   4 were the 
best responders to Exelon therapy.
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